Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure.
Doxorubicin
Pegylated-liposomal doxorubicin
Sarcoma
Journal
Clinical sarcoma research
ISSN: 2045-3329
Titre abrégé: Clin Sarcoma Res
Pays: England
ID NLM: 101577890
Informations de publication
Date de publication:
2019
2019
Historique:
received:
24
09
2018
accepted:
04
12
2018
entrez:
18
1
2019
pubmed:
18
1
2019
medline:
18
1
2019
Statut:
epublish
Résumé
Doxorubicin is one of the most active drugs available for the treatment of sarcoma. Pegylated-liposomal doxorubicin (PLD) is a formulation of doxorubicin in which the doxorubicin is encapsulated in liposomes coated with methoxypoly (ethylene glycol); this formulation results in decreased uptake by the reticuloendothelial system, higher concentrations of drug in tumor, and less toxicity, including reduced cardiotoxicity, nausea, alopecia, and myelosuppression. No premedication is necessary. While PLD has a better toxicity profile than free doxorubicin, there is no consensus on the relative efficacy of PLD and free doxorubicin in sarcoma. In this report, we describe a patient with high-grade metastatic soft tissue sarcoma with rapid recurrence after adjuvant treatment with free doxorubicin, cisplatin, ifosfamide, and dacarbazine. Second-line treatment with PLD resulted in long-term disease remission during a 20-year follow-up period. Mucositis and hand-foot syndrome were controlled by adjustment of dose and treatment interval. This case illustrates the curative potential of PLD after failure of free doxorubicin and the absence of long term cardiotoxicity with PLD. As with all drugs, individual adjustment of dose and treatment interval is important.
Sections du résumé
BACKGROUND
BACKGROUND
Doxorubicin is one of the most active drugs available for the treatment of sarcoma. Pegylated-liposomal doxorubicin (PLD) is a formulation of doxorubicin in which the doxorubicin is encapsulated in liposomes coated with methoxypoly (ethylene glycol); this formulation results in decreased uptake by the reticuloendothelial system, higher concentrations of drug in tumor, and less toxicity, including reduced cardiotoxicity, nausea, alopecia, and myelosuppression. No premedication is necessary. While PLD has a better toxicity profile than free doxorubicin, there is no consensus on the relative efficacy of PLD and free doxorubicin in sarcoma.
CASE PRESENTATION
METHODS
In this report, we describe a patient with high-grade metastatic soft tissue sarcoma with rapid recurrence after adjuvant treatment with free doxorubicin, cisplatin, ifosfamide, and dacarbazine. Second-line treatment with PLD resulted in long-term disease remission during a 20-year follow-up period. Mucositis and hand-foot syndrome were controlled by adjustment of dose and treatment interval.
CONCLUSIONS
CONCLUSIONS
This case illustrates the curative potential of PLD after failure of free doxorubicin and the absence of long term cardiotoxicity with PLD. As with all drugs, individual adjustment of dose and treatment interval is important.
Identifiants
pubmed: 30651969
doi: 10.1186/s13569-018-0111-0
pii: 111
pmc: PMC6332634
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1Références
Cancer. 1999 Jul 1;86(1):72-8
pubmed: 10391566
Anticancer Res. 2000 Jan-Feb;20(1B):485-91
pubmed: 10769710
Eur J Cancer. 2001 May;37(7):870-7
pubmed: 11313175
Cancer Invest. 2003 Apr;21(2):167-76
pubmed: 12743981
Cancer Res. 1992 Dec 15;52(24):6774-81
pubmed: 1458465
Semin Oncol. 2004 Dec;31(6 Suppl 13):53-90
pubmed: 15717738
Semin Oncol. 2004 Dec;31(6 Suppl 13):161-81
pubmed: 15717742
Gynecol Oncol. 2005 Mar;96(3):749-52
pubmed: 15721421
Anticancer Drugs. 2009 Jan;20(1):15-20
pubmed: 19342997
Gynecol Oncol. 2013 Jun;129(3):544-7
pubmed: 23523653
Lancet Oncol. 2014 Apr;15(4):415-23
pubmed: 24618336
Lancet Oncol. 2014 Apr;15(4):366-7
pubmed: 24694628
Gynecol Oncol. 2015 Jun;137(3):503-7
pubmed: 25735254
J Clin Oncol. 2016 Mar 10;34(8):786-93
pubmed: 26371143
Cancer Chemother Pharmacol. 2017 Oct;80(4):787-798
pubmed: 28856562
Cancer. 1972 Dec;30(6):1632-8
pubmed: 4663966
Br Med J. 1969 Aug 30;3(5669):503-6
pubmed: 5257148
Cancer. 1994 Mar 1;73(5):1478-84
pubmed: 8111716
Cancer Res. 1994 Feb 15;54(4):987-92
pubmed: 8313389
J Clin Oncol. 1993 Jul;11(7):1269-75
pubmed: 8315424
Pharm Res. 1993 May;10(5):703-8
pubmed: 8321835
J Clin Pharmacol. 1996 Jan;36(1):55-63
pubmed: 8932544
J Clin Oncol. 1997 Feb;15(2):653-9
pubmed: 9053490
Anticancer Drugs. 1998 Jan;9(1):45-50
pubmed: 9491791
Ann Oncol. 1998 Oct;9(10):1131-3
pubmed: 9834828